Jan Zenka
Ceske Budejovice, JC, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Opsonization and timing as key determinants of MBTA immunotherapy efficacy in pancreatic adenocarcinoma and recurrence treatment.
Journal: Cancer biology & therapy
Published: June 19, 2026
Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model.
Journal: Best practice & research. Clinical endocrinology & metabolism
Published: September 15, 2024
rWTC-MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 31, 2023
rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses.
Journal: Journal of experimental & clinical cancer research : CR
Published: April 11, 2023
The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma.
Journal: International immunopharmacology
Published: January 11, 2023
Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy.
Journal: Frontiers in endocrinology
Published: August 28, 2022
Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy.
Journal: Cancers
Published: June 30, 2021
Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA).
Journal: Advanced therapeutics
Published: March 12, 2021
Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma.
Journal: International journal of molecular sciences
Published: February 26, 2021
Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations.
Journal: Cancer immunology, immunotherapy : CII
Published: February 06, 2020
Last Updated: 09/26/2026